Starling Oncology, Inc. (STLN)

Starling Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	41.09	33.57	49.67	33.49	14.01	114.3
Short-Term Investments	-	-	-	49.37	59.8	-
Cash & Short-Term Investments	41.09	33.57	49.67	82.86	73.81	114.3
Cash Growth	35.66%	-32.42%	-40.05%	12.26%	-35.43%	1805.62%
Accounts Receivable	66.35	59	48.34	42.36	39.82	20.01
Other Receivables	0.36	0.32	0.35	0.55	0.62	1.24
Receivables	66.71	59.32	48.68	42.91	40.43	21.24
Inventory	20.01	16.88	10.04	13.68	9.26	6.44
Prepaid Expenses	1.18	2.99	4.03	4.05	6.92	11.2
Restricted Cash	-	-	-	-	-	0.88
Total Current Assets	128.99	112.75	112.42	143.49	130.42	154.06
Property, Plant & Equipment	31.77	33.06	37.67	40.05	33.04	4.19
Long-Term Investments	-	-	-	-	58.35	-
Goodwill	7.23	7.23	7.23	7.23	21.42	26.63
Other Intangible Assets	9.59	11.02	14.81	17.9	17.96	18.25
Other Long-Term Assets	0.66	0.61	0.59	0.56	0.48	0.32
Total Assets	178.23	164.66	172.72	209.24	261.67	203.44

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	60.28	43.17	24.32	14.43	9.37	15.56
Accrued Expenses	20.58	11.5	9.28	10.7	9.42	8.33
Short-Term Debt	0.27	0.79	0.77	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.18
Current Portion of Leases	7.26	7.19	6.8	6.36	5.5	-
Current Income Taxes Payable	-	-	-	-	0.26	0.13
Current Unearned Revenue	-	2.28	2.35	1.09	1.14	0.26
Other Current Liabilities	6.55	6.02	8.69	2.21	4.04	5.33
Total Current Liabilities	94.94	70.96	52.22	34.79	29.72	29.8
Long-Term Debt	79.87	77.4	93.13	86.83	80.62	-
Long-Term Leases	17.39	19.16	23.22	26.49	22.06	-
Long-Term Deferred Tax Liabilities	-	-	0.03	0.03	0.11	0.37
Other Long-Term Liabilities	10.95	12.86	0.53	4.08	5.98	69.11
Total Liabilities	203.15	180.38	169.13	152.22	138.49	99.28

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	259.8	256.71	215.41	204.19	186.25	167.39
Retained Earnings	-283.7	-271.42	-210.81	-146.15	-63.08	-63.23
Treasury Stock	-1.02	-1.02	-1.02	-1.02	-	-
Total Common Equity	-24.91	-15.72	3.59	57.03	123.18	104.16
Shareholders' Equity	-24.91	-15.72	3.59	57.03	123.18	104.16
Total Liabilities & Equity	178.23	164.66	172.72	209.24	261.67	203.44

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	104.79	104.55	123.92	119.68	108.18	0.18
Net Cash (Debt)	-63.7	-70.98	-74.25	-36.82	-34.37	114.12
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.63	-0.77	-0.99	-0.50	-0.43	1.72
Filing Date Shares Outstanding	101.92	98.84	75.75	74.31	74.55	73.25
Total Common Shares Outstanding	100.47	98.86	75.74	74.15	73.27	73.25
Working Capital	34.05	41.79	60.2	108.71	100.7	124.26
Book Value Per Share	-0.25	-0.16	0.05	0.77	1.68	1.42
Tangible Book Value	-41.73	-33.97	-18.45	31.89	83.8	59.29
Tangible Book Value Per Share	-0.42	-0.34	-0.24	0.43	1.14	0.81
Machinery	9.47	7.42	6.05	5.84	3.88	2.11
Construction In Progress	0.56	1.14	0.11	1.8	1.14	0.52
Leasehold Improvements	13.25	12.85	12.5	9.21	6.66	3.39

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error